It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We report a covalent chemistry-based hepatocellular carcinoma (HCC)-specific extracellular vesicle (EV) purification system for early detection of HCC by performing digital scoring on the purified EVs. Earlier detection of HCC creates more opportunities for curative therapeutic interventions. EVs are present in circulation at relatively early stages of disease, providing potential opportunities for HCC early detection. We develop an HCC EV purification system (i.e., EV Click Chips) by synergistically integrating covalent chemistry-mediated EV capture/release, multimarker antibody cocktails, nanostructured substrates, and microfluidic chaotic mixers. We then explore the translational potential of EV Click Chips using 158 plasma samples of HCC patients and control cohorts. The purified HCC EVs are subjected to reverse-transcription droplet digital PCR for quantification of 10 HCC-specific mRNA markers and computation of digital scoring. The HCC EV-derived molecular signatures exhibit great potential for noninvasive early detection of HCC from at-risk cirrhotic patients with an area under receiver operator characteristic curve of 0.93 (95% CI, 0.86 to 1.00; sensitivity = 94.4%, specificity = 88.5%).
Extracellular vesicles (EVs) are present in circulation at relatively early stages of disease, providing potential opportunities for early cancer diagnosis. Here, the authors report a covalent chemistry-based hepatocellular carcinoma (HCC)-specific EV purification system for early detection of HCC by performing digital scoring on the purified EVs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



















1 University of California, California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); University of Chinese Academy of Sciences, Chinese Academy of Sciences, Key Laboratory for Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Suzhou, P.R. China (GRID:grid.458499.d) (ISNI:0000 0004 1806 6323)
2 University of California, California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
3 Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)
4 University of California, Department of Medicine, David Geffen School of Medicine, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
5 Cedars-Sinai Medical Center, Division of Cancer Biology and Therapeutics, Departments of Surgery, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)
6 Cedars-Sinai Medical Center, Comprehensive Transplant Center, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)
7 University of California, Department of Medicine, David Geffen School of Medicine, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); University of California, Department of Surgery, David Geffen School of Medicine, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
8 University of California, Department of Surgery, David Geffen School of Medicine, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); University of California, Jonsson Comprehensive Cancer Center, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
9 University of California, Department of Medicine, Statistics Core, David Geffen School of Medicine, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
10 Academia Sinica, Smart Organic Materials Laboratory, Institute of Chemistry, Taipei, Taiwan (GRID:grid.28665.3f) (ISNI:0000 0001 2287 1366)
11 Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905); Cedars-Sinai Medical Center, Division of Cancer Biology and Therapeutics, Departments of Surgery, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)
12 Cedars-Sinai Medical Center, Comprehensive Transplant Center, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905); Cedars Sinai Medical Center, Division of Digestive and Liver Diseases, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)
13 University of Chinese Academy of Sciences, Chinese Academy of Sciences, Key Laboratory for Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Suzhou, P.R. China (GRID:grid.458499.d) (ISNI:0000 0004 1806 6323)
14 University of California, California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); University of California, Jonsson Comprehensive Cancer Center, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)